Kala Pharmaceuticals
Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug application (IND) for its lead product candidate, KPI-012, a human Mesenchymal Stem Cell Secretome (MSC-S) for the treatment of persistent corneal epithelial defect (PCED).
Kala is a . . .
This content is for paid subscribers.
Today’s Highlights
December 28, 2022
